Avaliação de fatores angiogênicos e antiangiogênicos em pacientes com lúpus eritematoso sistêmico

• Ano de defesa: 2014
• Autor(a) principal: Jesús, Guilherme Ribeiro Ramires de
• Orientador(a): Klumb, Evandro Mendes
• Banca de defesa: Araujo, Denizar Vianna , Levy, Roger Abramino , Bica, Blanca Elena Rios Gomes , Pinheiro, Geraldo da Rocha Castelar
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade do Estado do Rio de Janeiro
• Programa de Pós-Graduação: Programa de Pós-Graduação em Ciências Médicas
• Departamento: Centro Biomédico::Faculdade de Ciências Médicas
• País: BR
• Palavras-chave em Português: Lúpus eritematoso sistêmico; Nefrite lúpica; Fator de crescimento do endotélio vascular; VEGF; PlGF; sFlt-1; Lúpus Eritematoso Sistêmico; Nefrite Lúpica Fisiopatologia; Fatores de Crescimento do Endotélio Vascular; Receptores Proteína Tirosina Quinases
• Palavras-chave em Inglês: Systemic lupus erythematosus; Lupus nephritis; Vascular endothelial growth factor; VEGF; PlGF; sFlt-1
• Área do conhecimento CNPq: CNPQ::CIENCIAS DA SAUDE::MEDICINA::CLINICA MEDICA::REUMATOLOGIA
• Link de acesso: http://www.bdtd.uerj.br/handle/1/8742

Systemic lupus erythematosus (SLE) is an autoimmune disease which pathophysiology involves immunological mechanisms including disturbances in the processes of cell death and mechanisms of elimination of autoantigens and tolerance, accompanied by formation of pathogenic autoantibodies. It mainly affects young women and pregnancy in these patients have significant morbidity and mortality. Clinical and laboratory findings in lupus nephritis are similar to those found in patients with preeclampsia (PE), specifically hypertension, proteinuria and edema. It has been proposed the use of angiogenic factors, such as vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), and antiangiogenic factors, as soluble Fms-like tyrosine kinase-1 (sFlt-1), for the differential diagnosis between these two conditions, however available data in the literature about these cytokines in non-pregnant SLE patients are inconsistent. This study was designed to evaluate whether there are differences between serum levels of VEGF, PlGF and sFlt-1 in SLE patients with and without systemic disease activity and whether there are differences in these factors when comparing SLE patients with healthy women. 54 women with SLE followed at outpatient clinic of Rheumatology HUPE - UERJ were included. They had no other autoimmune disease diagnosed and were divided according to disease activity. 30 patients had inactive disease (mean SLEDAI: 0.7), and 24 had active disease (mean SLEDAI: 11.6). 23 women in this latter group had active nephritis, while 20 patients with inactive disease had history of lupus nephritis. The control group consisted of 34 healthy women who attended the Gynecology outpatient clinic at Policlínica Piquet Carneiro - UERJ. Considering the three studied cytokines, the SLE patients had higher mean serum levels than the control group (VEGF: 319.0 + 226.0 x 206.2 + 119.4, p=0.02; PlGF: 42.2 + 54.1 x 13.6 + 21.6, p=0.02; sFlt-1: 107.9 + 49.2 x 70.2 + 95.0, p=0.01). The group of patients with active disease also had higher mean levels of all three factors than controls (VEGF: 331.0 + 216.8 x 206.2 + 119.4, p=0.02; PlGF: 41.2 + 47.3 x 13.6 + 21.6, p=0.02; sFlt-1: 120.5 + 42.4 x 70.2 + 95.0, p=0.02), whereas no statistical difference was found between the group with inactive SLE and the control group. The mean sFlt-1 levels were higher in patients with active SLE than the mean levels of patients with inactive disease (120.5 + 54.9 x 97.8 + 42.4, p=0.02), but there was no significant difference in mean serum of VEGF and PlGF levels between these two groups. A better understanding of angiogenic and antiangiogenic factors in patients with SLE provided by this study allows the analysis of these cytokines in pregnant woman with SLE and possibly their subsequent application as differential method between PE and lupus nephritis.